Promoting cost effective prescribing
- 15 April 1995
- Vol. 310 (6985) , 955-956
- https://doi.org/10.1136/bmj.310.6985.955
Abstract
Expensive drugs require the use of limited resources, which, once deployed are not available for other activities that may bring greater benefits for patients. When an expensive drug is shown to be cost effective, however, its use is justified by the additional benefits it brings. To use scarce resources efficiently the careful and explicit measurement of the value of what is given up (the opportunity cost) and the value of what is gained (for example, improvements in the length and quality of life) is essential. The measurement of cost alone or effectiveness alone will produce inefficiency as a rational health care system finances expensive alternatives to existing treatments only if these bring additional benefits commensurate with the cost.Keywords
This publication has 15 references indexed in Scilit:
- Systematic Reviews: Rationale for systematic reviewsBMJ, 1994
- Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicideBMJ, 1994
- What Price Depression?The British Journal of Psychiatry, 1994
- Something rotten in the state of clinical and economic evaluations?Health Economics, 1994
- Prenatal screening for trisomy 18: Should not be contemplatedBMJ, 1994
- The scandal of poor medical researchBMJ, 1994
- The Pharmaceutical Industry and Health Reform: Lessons From EuropeHealth Affairs, 1994
- Avoiding Bias in the Conduct and Reporting of Cost-Effectiveness Research Sponsored by Pharmaceutical CompaniesNew England Journal of Medicine, 1991
- The design of future cost-benefit studiesAmerican Heart Journal, 1990
- Assessing the clinical effectiveness of preventive maneuvers: Analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations A report by the Canadian task force on the periodic health examinationJournal of Clinical Epidemiology, 1990